Thanks @thevinnys - I love the back of the envelope calculation.
It will be very interesting to discover, as these therapies mature, how the various markets approach administering and subsidizing.
Even if the market potential in Australia is limited to $10-20M per annum in revenues, that's still a significant revenue stream to start building towards - but as you mention, like all Incannex's drug development programs, psi-GAD aims to capture the US market which is 15 times bigger. And of course the rest of the world in due course.
One thing is for certain: sadly GAD isn't going to go away on its own. The world is only getting more and more conducive to anxiety. We might find CAGR of this affliction may end up significantly higher than currently forecast by the time the decade is nearing completion.
- Forums
- ASX - By Stock
- IHL
- Ann: Independent data review commences for Ph 2 trial psilocybin
Ann: Independent data review commences for Ph 2 trial psilocybin, page-33
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online